Computer-Power-Engineering-Inc near Treherne MB (965 Result(s))

Meditek's Small BeginningsMeditek ,A centrally located in Winnipeg, MB, entered the Canadian medical industry in 1981.As a division of the family corporation that had been operating since 1962, Meditek was poised to provide nationwide support.A small service department was created in a little workshop with the vision of remanufacturingAmedical equipment .Today, Meditek still offers that same quality service of remanufacturing, even though we have diversified into many other areas of medical products and services.Defining Meditek's LegacyMeditek's core belief in reliability, quality and customer service remains unchanged. We carry these values forward every day.As we developed, we recognized that Canadian hospitals wanted and deserved better medical equipment conditions in their operating rooms.A This realization led to distribution growth of new medical equipment and products for a variety of manufacturers.At the same time, we continued to provide cost-effective medical equipment solutions for budget restrained hospitals in Canada through our unique remanufacturing program.Committed to remain the total solutions partner, Meditek's product development will never cease as we continuously develop new healthcare products and services to meet the requirements of tomorrow

Our ProductsAGGRASTAT® - US GP IIb/IIIa inhibitor market - $400 million (AGGRASTAT® + two competitors)TARDOXALTM - in Phase II clinical development for the treatment of Tardive Dyskinesia - a large, unmet needAbout MedicureMedicure is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics.HistoryMedicure founded in 1997 is a specialty pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. Medicure has raised over $140 million and focused this investment on the advancement and clinical development of cardiovascular drugs. In 2006 Medicure acquired the USA commercial rights to AGGRASTAT (tirofiban HCl), a cardiovascular drug originally developed by Merck. AGGRASTAT, in combination with heparin, is indicated for the treatment of acute coronary syndrome. Medicurés business is generating revenue to support operations and to make selected investments in the clinical advancement of AGGRASTAT.TodayMedicurés core focus is on the US commercial sales of its FDA approved small molecule, AGGRASTAT.

7% of Canadians have Macular DegenerationBy 2030, over 20% of Canadians will have Macular Degeneration1 in 9 of those over 65 have reduced visionResearch studies tell us that individuals who are legally blind would give up 60% of their remaining lifespan to see again1 in 4 of those over 80 have a vision impairmentEye Canada 2009 Helping You See BetterFocusing on Low Vision Care in Canada 2-1200 Waverley Street, Winnipeg, Manitob,a Canada

With Fido get phones and plans that are low on price and high on benefits with 5 extra hours of data each month and perks every Thursday with Fido XTRA. So, wherever life takes you, go get it.